From Inquiry to Investigation to Insight: Clinical Clarity in Non-Small Cell Lung Cancer
A comprehensive update on recent advances in evidence-based care for patients with non–small cell lung cancer. This activity includes expert perspectives on options for testing, managing disease in the early stages to metastatic stages, the advent of immunotherapy and targeted therapy, and how to manage the potential adverse events of these novel agents.
Click on any of the video presentations below to get started!
From Inquiry to Investigation to Insight: Clinical Clarity in Non–Small Cell Lung Cancer
A continuing education activity for nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.
These activities, certified for CME/CE/CPE credit, are jointly provided by:
|
Release date: December 10, 2019 |
Estimated time to complete activity: Up to 5.50 hour |
|
Expiration date: December 10, 2020 |
|
|
Certified for CE by: |
|
|
Annenberg Center for Health Sciences at Eisenhower |
Journal of the Advanced Practitioner |
This activity is supported, in part, by educational grants from AstraZeneca, Bristol-Myers Squibb Company and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Faculty
Beth Eaby-Sandy, MSN, CRNP, Conference Chair, Abramson Cancer Center, Philadelphia, Pennsylvania
Tyler Beardslee, PharmD, Winship Cancer Institute at Emory University, Atlanta, Georgia
Marianne Davies, DNP, ACNP, AOCNP®, Yale School of Nursing, New Haven, Connecticut
Elizabeth Gilbert, MS, PA-C, Abramson Cancer Center, Philadelphia, Pennsylvania
Rasheda Persinger, NP-C, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland
Learning Objectives
After completing this educational activity, participants should be able to:
- Evaluate recent updates regarding biomarker testing and molecular profiling used to guide management decisions for metastatic non–small cell lung cancer (NSCLC)
- Devise treatment plans for patients with locally advanced NSCLC
- Evaluate efficacy and safety data supporting the use of targeted and immune checkpoint inhibitor therapy used to treat NSCLC
- Select therapy in accordance with evidence-based best practices
- Apply clinical approaches to mitigate adverse events associated with targeted and immune checkpoint inhibitor therapy
- Manage drug–drug and drug–disease interactions in NSCLC
Continuing Education
Statement of Credit
Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.
Accreditation and Designation Statements
Physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, Harborside Medical Education, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 5.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses. Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 5.50 contact hours may be earned for successful completion of this activity.
Provider is approved by the California Board of Registered Nursing, Provider No. 13664, for 5.50 contact hours.
Pharmacists.
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program #0797-9999-19-140-H01-P. This program is designated for up to 5.50 contact hours (0.55 CEU) of continuing pharmacy education credit. This is a knowledge-based activity.
Disclosures
Relationships of Faculty and Planners
All individuals in a position to control the content of this activity (e.g., planners, faculty, reviewers) must disclose all financial relationships with commercial interests that may have a bearing on its subject matter. The Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with its policies and procedures. Participants should assess the impact (if any) of the disclosed information on the educational value of the activity.
Faculty
Ms. Eaby-Sandy, Conference Chair, has served as a consultant and on speakers bureaus for AstraZeneca, Helsinn, Merck, and Takeda.
Dr. Beardslee has served as a consultant for AstraZeneca and Herron, and on the speakers bureau for AstraZeneca.
Dr. Davies has served on speakers bureaus for AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck.
Ms. Gilbert has no conflicts of interest to disclose.
Ms. Persinger has served on speakers bureaus for Genentech and Guardant Health, and on the advisory board for AstraZeneca.
Planners
Staff at the Annenberg Center for Health Sciences at Eisenhower, Harborside, and Harborside Medical Education have nothing to disclose
Dorothy Caputo, MA, BSN, RN, EduPro Resources, LLC, has nothing to disclose.
Reviewer
Elizabeth Waxman, RN, MSN, AOCN®, ANP-BC, has nothing to disclose.
Product Disclosure
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food & Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.
Disclaimer
The opinions expressed in this activity are those of the faculty and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any therapeutic agent or approach to diagnosis or patient management.
How to Earn Credit
To access the learning assessment and evaluation form online, visit https://education.annenberg.net/5740-EM1
Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.
Disease Overview Followed by Selecting Treatments Using Biomarker Testing and Molecular Profiling
Review of strategies for planning therapy based on results of biomarker tests, liquid biopsies, as well as next-generation sequencing and tumor mutational burden profiles.
Posted: December 10, 2019 / Expires: December 10, 2020
This certified activity has expired but you may watch the video without claiming credit.
Managing Early-Stage and Locally Advanced NSCLC
Discussion of evidence-based management of disease using a multimodal approach that includes surgery, adjuvant chemotherapy, chemoradiation, and immunotherapy.
Posted: December 10, 2019 / Expires: December 10, 2020
This certified activity has expired but you may watch the video without claiming credit.
The Role of Immune Checkpoint Inhibitors With and Without Combination Therapy for Nonmutated Metastatic NSCLC
Analysis of therapeutic approaches using immune checkpoint inhibitors alone or with other agents in first-line setting and beyond.
Posted: December 10, 2019 / Expires: December 10, 2020
This certified activity has expired but you may watch the video without claiming credit.
Managing Immune-Related Adverse Events
Review of clinical and patient education strategies for identifying, mitigating, and addressing adverse events associated with immune checkpoint inhibitors.
Posted: December 10, 2019 / Expires: December 10, 2020
This certified activity has expired but you may watch the video without claiming credit.
Managing EGFR+ Metastatic NSCLC
Overview of the rationale for targeting EGFR-mutated NSCLC, followed by an evaluation of clinical data and best practices supporting the safe and effective use of EGFR inhibitors in the first-line setting and beyond.
Posted: December 10, 2019 / Expires: December 10, 2020
This certified activity has expired but you may watch the video without claiming credit.
Managing ALK+ and ROS1+ Metastatic NSCLC
Description Overview of the rationale for targeting ALK- and ROS1-mutated NSCLC, followed by an evaluation of clinical data and best practices supporting the safe and effective use of ALK inhibitors in the first-line setting and beyond.
Posted: December 10, 2019 / Expires: December 10, 2020
This certified activity has expired but you may watch the video without claiming credit.
Managing Patients With Other Mutations in Metastatic NSCLC and Upcoming Clinical Trials
Evaluation of the rationale for and clinical data supporting targeting driver mutations in NSCLC, such as BRAF, KRAS, and RET. Appraisal of clinical trials planned or in progress in lung cancer for which preliminary or updated data release has occurred in the past 12 months or is expected in the next 6 months. Discussion of new approvals for small cell lung cancer.
Posted: December 10, 2019 / Expires: December 10, 2020
This certified activity has expired but you may watch the video without claiming credit.
Identifying and Avoiding Drug Interactions
Discussion of best practices for mitigating drug-drug interactions and drug-disease interactions.
Posted: December 10, 2019 / Expires: December 10, 2020
This certified activity has expired but you may watch the video without claiming credit.
Consult the Experts: Case Challenges From Conference Participants
Discussion of clinical decision points involved in challenging patient cases, with a focus on how patient disease characteristics and personal preferences can be used to guide clinical decision-making.
These activities, certified for CME/CE/CPE credit, are jointly provided by
| |